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Abstract
Stromal interaction molecules (STIM) were identified as the endoplasmic-reticulum (ER) Ca
2+ sensor controlling
store-operated Ca
2+ entry (SOCE) and Ca
2+-release-activated Ca
2+ (CRAC) channels in non-excitable cells. STIM
proteins target Orai1-3, tetrameric Ca
2+-permeable channels in the plasma membrane. Structure-function analysis
revealed the molecular determinants and the key steps in the activation process of Orai by STIM. Recently, STIM1
was found to be expressed at high levels in skeletal muscle controlling muscle function and properties. Novel STIM
targets besides Orai channels are emerging.
Here, we will focus on the role of STIM1 in skeletal-muscle structure, development and function. The molecular
mechanism underpinning skeletal-muscle physiology points toward an essential role for STIM1-controlled SOCE to
drive Ca
2+/calcineurin/nuclear factor of activated T cells (NFAT)-dependent morphogenetic remodeling programs
and to support adequate sarcoplasmic-reticulum (SR) Ca
2+-store filling. Also in our hands, STIM1 is transiently
up-regulated during the initial phase of in vitro myogenesis of C2C12 cells. The molecular targets of STIM1 in these
cells likely involve Orai channels and canonical transient receptor potential (TRPC) channels TRPC1 and TRPC3. The
fast kinetics of SOCE activation in skeletal muscle seem to depend on the triad-junction formation, favoring a pre-
localization and/or pre-formation of STIM1-protein complexes with the plasma-membrane Ca
2+-influx channels.
Moreover, Orai1-mediated Ca
2+ influx seems to be essential for controlling the resting Ca
2+ concentration and for
proper SR Ca
2+ filling. Hence, Ca
2+ influx through STIM1-dependent activation of SOCE from the T-tubule system
may recycle extracellular Ca
2+ losses during muscle stimulation, thereby maintaining proper filling of the SR Ca
2+
stores and muscle function. Importantly, mouse models for dystrophic pathologies, like Duchenne muscular
dystrophy, point towards an enhanced Ca
2+ influx through Orai1 and/or TRPC channels, leading to Ca
2
+-dependent apoptosis and muscle degeneration. In addition, human myopathies have been associated with
dysfunctional SOCE. Immunodeficient patients harboring loss-of-function Orai1 mutations develop myopathies,
while patients suffering from Duchenne muscular dystrophy display alterations in their Ca
2+-handling proteins,
including STIM proteins. In any case, the molecular determinants responsible for SOCE in human skeletal muscle
and for dysregulated SOCE in patients of muscular dystrophy require further examination.
Review
STIM is the ER Ca
2+ sensor that controls Orai-mediated
store-operated Ca
2+ influx
For about 20 years after the initial concept of store-oper-
ated Ca
2+ entry (SOCE) was proposed by Putney [1,2],
the molecular candidates underpinning SOCE remained
elusive. In 2005 and 2006, key players for SOCE in non-
excitable cells were identified via RNAi screens in Droso-
phila [3] and HeLa cells [4], which elucidated STIM
proteins as the endoplasmic-reticulum (ER) Ca
2+ sensor
and Orai proteins [5-7] as the Ca
2+-permeable store-
operated Ca
2+ channel or Ca
2+-release activated Ca
2+
(CRAC) channel [8,9]. In mammals, two STIM genes,
STIM1 and STIM2,a n dt h r e eO R A Ig e n e s ,ORAI1,
ORAI2 and ORAI3, have been identified [5-7]. Different
reports confirmed that STIM1 and Orai1 are the molecu-
lar candidates for currents with the electrophysiological
properties of the CRAC channel [10-12]. These proper-
ties include a high selectivity for Ca
2+ over monovalent
ions, like Na
+ and K
+, and a single-channel Ca
2+ conduc-
tance of about 30 fS, which is about 100 times smaller
than the conductance of L-type Ca
2+ channels [13,14].
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intracellular Ca
2+ store [4,15-17]. The ER-resident
STIM1 controls Orai function by activating these chan-
nels upon ER Ca
2+-store depletion [3,12,17-19]. Recently,
the different steps involved in the STIM1-dependent acti-
vation of Ca
2+ influx upon store depletion have been
identified [15,16,20,21]. These steps include the sensing
of Ca
2+ depletion from the ER, dissociation of Ca
2+ from
the EF-hand motif of STIM1, the rapid oligomerization
of STIM1, the translocation of STIM1 into punctae con-
sisting of close ER/plasma-membrane junctions and the
activation of plasma-membrane Ca
2+-influx channels (see
[13,14] for recent reviews).
STIM1 (approximately 75 kDa) contains an intraluminal
region of approximately 22 kDa, a single transmembrane
domain and a cytosolic region of approximately 51 kDa.
The functional intraluminal ER Ca
2+ sensor of STIM1 is
the first of two EF-hand domains (EF1; aa 63-96), which
precedes a second EF-hand domain (EF2; aa 97-128) and a
sterile a-motif domain (SAM; aa 131-200) [13,22]. The
cytosolic domain consists of two or three coiled-coil
domains within an ezrin-radixin moesin (ERM) domain, a
serine/proline-rich (S/P) domain and a polybasic lysine-
rich (KKK) domain. Structural analysis of the recombi-
nantly expressed EF-SAM domain (aa 58-201) revealed
that Ca
2+ is bound to the first EF-hand domain. EF-SAM
exists in a monomeric state when Ca
2+ is bound because
of close interaction of the paired EF hands and SAM
[22,23]. When Ca
2+ dissociates, protein unfolding triggers
major structural rearrangements of EF-SAM and the accu-
mulation of dimer and aggregated forms of EF-SAM are
observed [22,23]. In vitro experiments revealed a Kd of
about 500-600 μMf o rC a
2+ binding to EF-SAM [23],
which is in the range of Ca
2+ concentration ([Ca
2+]) in the
ER [21].
Ca
2+ dissociation from EF1 of STIM1 causes its oligo-
merization [22,23] and underpins the sequential changes
upon ER Ca
2+-store depletion [20]. Mutations in EF1
disrupting the Ca
2+-binding properties of STIM1 or
mutations in EF2 and SAM domain destabilizing the
interaction between the EF-hand domains and SAM,
result in a constitutively active STIM1 and activation of
Orai proteins, resembling their state during depleted ER
Ca
2+ stores [4,17]. Oligomerization of STIM1 is closely
related to activation of CRAC, since artificial oligomeri-
zation of the STIM1 cytosolic domains was sufficient to
trigger punctae formation and Ca
2+ influx [21]. These
results indicate that the oligomerization of STIM1 is the
switch that controls SOCE upon ER Ca
2+-store depletion
via STIM1/Orai1 clustering at ER/plasma-membrane
junctions [21].
Upon STIM1 oligomerization, STIM1 redistributes to
sites of close apposition of ER and plasma membrane
[15,16,24]. The kinetics of STIM1 redistribution is in
the order of tens of seconds and involves local diffusion
in the ER membranes, while interaction with specific
lipids or proteins may facilitate the accumulation of ER/
plasma-membrane contact sites [4,16,20]. Two factors
seem to contribute to STIM1 relocalization: i) protein-
lipid interactions, mediated by the interaction of the
polybasic C-terminus of STIM1 with plasmalemmal
phospholipids like phosphatidylinositol 4,5-bisphosphate
and phosphatidylinositol 3,4,5-trisphosphate, and ii) pro-
tein-protein interactions, mediated by the direct interac-
tion of STIM1 with the C-terminus of Orai [20,25-28].
The latter interactions are proposed to contribute to
the recruitment of Orai1 to ER/plasma-membrane junc-
tions. Indeed, C-terminal truncation of Orai1 fails to co-
localize with STIM1 punctae and hence fails to mediate
CRAC currents upon store depletion [29,30]. A final
step in the activation process is the opening of the tetra-
meric, Ca
2+-selective Orai1 channels. In vitro Ca
2+-flux
assays revealed that Orai1 channels are directly gated by
STIM1 [31]. The N-terminal cytosolic domain of Orai1
seems critical for Orai1-channel opening [30], possibly
involving a direct binding of STIM1 to aa 65-91 of
Orai1 [26,29,31]. Recently, the minimal region of STIM1
involved in CRAC activation was identified as the
CRAC-activating domain (CAD, aa 342-448), also
known as the STIM1-Orai1-activating region (SOAR, aa
344-442) [26,32-34].
Very recently, Orai1 channels were shown to be
directly activated by the SPCA2, a Ca
2+ pump belonging
to the secretory-pathway Ca
2+ ATPases [35]. SPCA2
expression potentiated Ca
2+ influx through Orai1 chan-
nels, independently of STIM proteins or SPCA2 Ca
2
+-ATPase activity. The mechanism involves a two-step
activation mechanism and interaction of two parts of
SPCA2: binding of the N-terminal region of SPCA2 to
Orai1 enables SPCA2’s C-terminus to access and activate
Orai1 [35]. These findings are clinically relevant, since
SPCA2 is up-regulated in breast tumors and SPCA2
knockdown decreases tumorigenicity.
STIM2 is very similar to STIM1 in basic structure and
functional properties [4,36]. STIM2 senses luminal ER
Ca
2+ via two EF-hands. Ca
2+ dissociation from STIM2
leads to a conformational change, oligomerization and
redistribution to ER/plasma-membrane contact sites [4].
The redistribution of STIM2 seems to occur at higher ER
[Ca
2+], that is, at smaller decreases in ER, than the redis-
tribution of STIM1 [Ca
2+] [37]. In this perspective,
STIM2 has been identified in an siRNA screen as a criti-
cal feedback regulator of basal cytosolic and ER [Ca
2+]
[37]. Knockdown of STIM2 markedly lowers the basal
cytosolic and ER [Ca
2+], while knockdown of STIM1 has
less effect. However, these features may be dependent on
the cell type and/or levels of STIM2, since basal [Ca
2+]a s
well as the thapsigargin-releasable Ca
2+ did not differ
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cells and MEF cells deficient for STIM2 [38]. Similar
findings were observed using an overexpression
approach, in which STIM2 overexpression increased
basal cytosolic [Ca
2+], markedly more than STIM1 over-
expression. Consistent with these findings, small reduc-
tions in ER [Ca
2+]c a u s e dS T I M 2 ,b u tn o tS T I M 1 ,
translocation and redistribution to punctae, with subse-
quent activation of Ca
2+ influx [37]. While both STIM1
and STIM2 have been implicated in triggering Ca
2+
influx following receptor-mediated ER Ca
2+-store deple-
tion [37,39], STIM1
-/- cells displayed more severe defects
in SOCE than STIM2
-/- cells [38,39]. From agonist-
induced Ca
2+ release in STIM1
-/- and STIM2
-/- cells, it
was found that STIM2, but not STIM1, is dispensable for
agonist-induced Ca
2+ signaling [38]. Nevertheless, the
sustained nuclear localization of NFAT and production
of cytokines are severely hampered in STIM2
-/- Tc e l l s
[39].
The fundamental biological role of STIM/Orai sig-
naling is indicated by the fact that recessive mutations
in STIM or Orai affecting their molecular function
lead to severe hereditary immunodeficiency in humans
[13]. Different mutations in STIM1 as well as Orai1
leading to loss-of-functiono rl o s s - o f - e x p r e s s i o no f
these proteins have been identified in immunodeficient
patients [5,40-42]. Importantly, these defects can be
overcome by STIM1 or Orai1 overexpression, but not
by STIM2 or Orai2/3, indicating a predominant role
for STIM1/Orai1 in T-cell Ca
2+-signaling function.
Loss of STIM1/Orai1 signaling in patients results in
severe T-cell immunodeficiency and concomitant viral,
bacterial and fungal infections [41-44]. Strikingly, a
congenital, nonprogressive myopathy is consistently
observed in infant patients, indicating that STIM1 not
only plays a crucial role in T-cell activation and prolif-
eration, but also in skeletal-muscle function and/or
development (see part 3) [42].
Other targets of STIM proteins
A detailed discussion on STIM targets can be found in
[13].
Microtubule-plus-end-tracking protein EB1
STIM1 is recruited by end-binding protein-1 (EB1) to
sites of physical contact between growing microtubule
tips and ER [45,46]. However, the contribution of micro-
tubule-associated STIM1 to Ca
2+ signaling is not clear.
Preventing STIM1 localization at the microtubule does
not directly affect SOCE [45] and microtubules are not
essential for initial CRAC channel gating in T cells and
mast cells [47,48]. Indirect effects of the association of
STIM1 with the microtubule may be caused by remo-
deling of the ER or ER/plasma-membrane contact sites
or the availability of STIM1.
Canonical transient receptor potential (TRPC) channels
Other candidates for SOCE include TRPC channels
[25,49]. Biochemical and functional experiments
revealed that STIM1 directly interacts with TRPC chan-
nels through electrostatic interaction, which involves the
K864/K865 in the polybasic lysine-rich region of STIM1
and two negative charges that are conserved in all
TRPC channels, that is, D639/D640 in TRPC1 and
D697/D698 in TRPC3 [50]. STIM1 was shown to
directly bind and regulate TRPC1, TRPC4 and TRPC5,
while indirect actions of STIM1 on TRPC3 and TRPC6
have been proposed [49]. STIM1-dependent gating of
TRPC channels seem to differ from their gating of Orai
channels, pointing towards an independent gating
mechanism of TRPCs versus Orai channels by STIM1
[50]. Nevertheless, the regulation of TRPC channels by
STIM1 has been questioned in a very diligent study per-
formed by the Putney lab [51], in which endogenous
and ectopic TRPC1-, TRPC3-, TRPC5-, TRPC6- and
TRPC7-mediated Ca
2+ entry was unaffected by increased
or decreased STIM1 levels. A detailed discussion on the
role of STIM1 in regulating Orai versus TRPC channels
can be found in a recent review [52].
Arachidonate-regulated Ca
2+-selective (ARC) channel
Another target of STIM1 is the ARC channel, a receptor-
operated Ca
2+-entry channel whose activation is comple-
tely independent of store depletion or of translocation of
ER-resident STIM1 [53,54]. It is proposed that a fraction
of STIM1 constitutively residing at the plasma membrane
is responsible for the regulation of the activity of the
ARC channels, since antibodies targeting plasmalemmal
STIM1 or mutating its N-linked glycosylation sites essen-
tial for its cell-surface expression inhibited ARC-channel
activity. Recent work identified the molecular architec-
ture of ARC channels, revealing a pentameric organiza-
tion consisting of three Orai1 and two Orai3 subunits
[ 5 5 ] .T h i sd e v i a t e sf r o mt h et e trameric structure of Orai
channels mediating CRAC currents.
Adenylate cyclase (AC)
A recent study revealed a novel role for STIM1 where it
participated in the store-operated recruitment of AC
[56]. Indeed, depleting ER Ca
2+ stores led to the recruit-
ment of AC to the intracellular Ca
2+ stores, resulting in
increased cAMP levels and enhanced signaling by pro-
tein kinase A. This process was shown to be indepen-
dent of increases in cytosolic [Ca
2+], but required the
translocation of STIM1. This study therefore points out
that STIM1 may be an important integrator molecule
that mediates cross-talk between Ca
2+-dependent signal-
ing and cAMP-dependent signaling. Recently, STIM1-
mediated store-operated cAMP signaling has been
implicated in the downstream effects of Ca
2+ signaling
induced by eicosapentaenoic acid, an omega-3 polyunsa-
turated fatty acid present in fish oil [57].
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2+ channel Cav1.2
In addition to the well-described Orai targets of STIM1,
two very recent studies identified the voltage-operated
Ca
2+ channel Cav1.2 as a novel target of STIM1 [58,59].
STIM1 targeted the a1c pore-forming subunit via a
direct interaction, thereby imposing an inhibitory con-
trol over Cav1.2 upon ER Ca
2+-store depletion, indepen-
dently of Orai1-channel activity or changes in cytosolic
[Ca
2+]. The mechanism involves the direct binding of
CAD or SOAR to a region encompassing aa 1809-1908,
located in the C-terminus of Cav1.2.
Importantly, while CAD or SOAR activates Orai1-
mediated currents, they inhibit Cav1.2-mediated cur-
rents. The interaction of STIM1 with the C-terminus of
Cav1.2 is critical for its inhibition. This process is inde-
pendent of functional Orai1-channel activity, but Orai1
may help STIM1-mediated Cav1.2 inhibition by trapping
STIM1 in punctae that contain Cav1.2 channels, thereby
recruiting STIM1 in the vicinity of Cav1.2 channels. In
addition, STIM1 expression seems to regulate the
plasma-membrane level of Cav1.2 [59]. Overexpression
of STIM1 caused a prominent decrease in the amount
of Cav1.2 at the plasma membrane, leading to STIM1/
Cav1.2 co-localization in intracellular vesicles and the
internalization of the channels.
The molecular targeting of STIM1 in Cav1.2 and
Orai1-related Ca
2+-influx pathways may be the molecu-
lar switch that accounts for the reciprocal regulation of
voltage-gated Ca
2+ influx (inhibition) and store-operated
Ca
2+ influx (activation) [58,59]. Interestingly, only exci-
table cells are able to increase cytosolic [Ca
2+]i n
response to membrane depolarization, although immune
cells (T cells, B cells, dendritic cells and mast cells) also
express voltage-gated Ca
2+ channels [60,61]. In contrast,
only non-excitable cells display prominent CRAC-chan-
nel activity upon store depletion, while SOCE is only a
minor component of Ca
2+ influx in excitable cells
[62,63]. However, excitable cells, like smooth-muscle
cells [64,65], neurons [66] and skeletal-muscle cells [63],
do express STIM1. The high expression level of STIM1
in skeletal muscle is supported by data obtained from
BioGPS (http://biogps.gnf.org/), an online gene annota-
tion portal (Figure 1) [67,68]. Since Cav1.2 and Orai
activate different downstream Ca
2+-signaling cascades
that control growth [65], differentiation [63] and cell
death [66], it is likely that STIM1 is a novel key player
with different functions in these cell types.
STIM1 in skeletal muscle
SOCE mechanism in skeletal muscle
SOCE in skeletal muscle was originally described in a
study from Kurebayashi and Ogawa [69]. They discovered
in thin muscle-fiber bundles of the extensor digitorum
longus (EDL) muscle of adult mice, that the depletion of
the SR by repetitive high-K
+ stimulation in the presence of
sarcoplasmic/endoplasmic-reticulum Ca
2+ ATPase
(SERCA) inhibitors triggered SOCE with the same charac-
t e r i s t i c sa st h eC R A Cc u r r e n t .T h i sp a t h w a yi sd i s t i n c t
from the excitation-coupled Ca
2+ entry, which is store-
independent [62]. Both pathways consist of distinct mole-
cular components and activation mechanisms [62]. Ca
2+
entry is important for store repletion [69], limiting fatigue
under conditions of extensive exercise [70], activation of
NFAT [63,71] and muscle differentiation [72]. Hence, it is
becoming increasingly clear that dysregulation of Ca
2+
entry may lead to severe muscle pathologies [73-75].
In general, we will limit our discussion to SOCE and we
will refer to other reviews for excitation-coupled Ca
2+
entry [76,77].
Four models for SOCE in skeletal muscle have been
proposed, including the conformation coupling between
i) ryanodine receptors (RyRs) and TRPCs, ii) inositol
1,4,5-trisphosphate receptors (IP3Rs) and TRPCs,
iii) STIM1 and Orai1 and iv) STIM1 and TRPC chan-
nels [76]. Figure 2 shows the molecular determinants
involved in SOCE in skeletal muscle with indication of
the outside-inside coupling between the dihydropyridine
receptor (DHPR), the skeletal-muscle type-1 RyR (RyR1)
and the inside-outside SOCE-coupling mechanisms via
STIM1/Orai1 and STIM1/TRPC.
Different studies proposed a role for conformational
coupling of RyRs to TRPCs, thereby activating SOCE
through TRPC channels [71,73,78]. However, RyRs are
likely not essential for SOCE in skeletal muscle, since
myotubes of mice lacking RyR1/RyR3 still display pro-
minent SOCE [62,70]. Consistent with this, Lee and
et al. did not find any role for TRPC3 in Ca
2+ entry in
skeletal muscle although its expression level increased
during differentiation [79]. The authors proposed that
the functional interaction between RyR1 and TRPC3
enhances RyR1 Ca
2+-release-channel activity and is thus
required for adequate SR Ca
2+ release.
Another candidate proposed was the coupling between
IP3Rs and TRP-family members [80,81], like TRPC3
[82]. However, the expression level of IP3Rs in myotubes
is relatively low and their localization is rather around
the nuclear envelope than at the SR terminal cisternae
(TC) [83,84].
The identification of STIM1 as the ER Ca
2+-sensor
protein and its conformational coupling to Orai1 chan-
nels controlling SOCE in T lymphocytes spurred the
idea that STIM1/Orai1 may be the molecular players
underlying SOCE also in skeletal muscle. Different lines
of evidence support the idea that STIM1 is critical for
SOCE in skeletal muscle: i) STIM1 and Orai1 are highly
expressed in skeletal muscle (Figure 1) [63,85], ii)
STIM1 is pre-localized at the SR junctions with the
T-tubule system which contains pre-localized Orai1
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thy [63], iv) severe combined immunodeficiency (SCID)
patients characterized by loss-of-function mutations in
STIM1/Orai1 signaling display skeletal-muscle myopathy
[5], and v) knockdown of STIM1 or expression of the
dominant negative Orai1 E106Q caused a marked
decline in SOCE in skeletal-muscle myotubes [62].
Besides Orai channels, a role for a conformational cou-
pling between STIM1 and TRPC channels in skeletal
muscle can however not be excluded. TRPC1 and TRPC3
channels have been shown to be expressed in skeletal
muscle and have been implicated in SOCE in lympho-
cytes [25]. Moreover, STIM1/Orai1/TRPC1-ternary com-
plexes have been shown to assemble during store
depletion, thereby contributing to SOCE [49,50,86]. The
C-terminal domain of STIM1 has been shown to directly
bind and activate TRPC1 upon ER Ca
2+-store depletion.
Furthermore, in a recent study using whole-cell patch-
clamp recordings approximately 60% of primary
myotubes displayed an inwardly rectifying current with
characteristics typical for CRAC current, while approxi-
mately 40% of myotubes displayed linear current-voltage
relationships, which may be related to store-operated
activation of TRPC channels [63]. These observations are
in line with evidence obtained from myoblasts, which dis-
played a decrease in SOCE upon repression of TRPC1
expression, thereby affecting myoblast migration and dif-
ferentiation [87]. However, while mice lacking TRPC1
display a muscle phenotype with muscle fibers that have
a decreased cross-sectional area, a reduced force genera-
tion, a decline in the level of myofibrillar proteins and a
decreased resistance towards muscle fatigue, the role of
TRPC1 in adult fibers seemed independent of the Ca
2
+-store content [88]. The work of Gailly and others indi-
cates that the role of TRPC1 in SOCE is dependent on
factors that differ among myoblasts and adult fibers
[87,88]. A pivotal role for the a-isoform of the inhibitor
of myogenic family (I-mfa) has been proposed, since
I-mfa binds and inhibits TRPC1 and myogenic factors
interfere with these complexes to alleviate TRPC1 inhibi-
tion by I-mfa [89,90]. Hence, in myoblasts, TRPC1 may
drive the onset of differentiation through a store-
controlled mechanism, while in adult fibers TRPC1 may
sustain endurance by maintaining force production upon
repeated stimulation and proper muscle development
through a store-independent mechanism.
Figure 1 Tissue distribution of Stim1, Stim2, Orai1-3 and Trpc1 in mouse. Data were extracted from the BioGPS database (http://biogps.gnf.
org/) and represent the mRNA expression patterns in selected mouse tissues [67,68]. Stim1 is strongly expressed in skeletal muscle and mast cells,
while Stim2 exhibits a relatively higher expression level in all tissues tested with pronounced expression in salivary-gland tissue. Orai1 expression is
stronger in skeletal muscle, while there is low expression of all Orai in other tissues presented here. Trpc1 expression is relatively low in both heart
and skeletal-muscle tissue, but higher in tissue of the central nervous system, such as in the cerebellum. These patterns do not necessarily reflect
the expression at the protein level or the situation in humans, but provide a good view of the patterns observed in mouse models.
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consequences for SOCE activation
While the molecular determinants responsible for SOCE
are very similar among T lymphocytes and skeletal-muscle
cells, there are also some striking differences, which may
be related to the pre-localization of STIM1/Orai1 and the
putative contribution of voltage-gated Ca
2+ channels in
the targeting of STIM1 to the TC/T-tubule junctions.
Indeed, a clear distinction between SOCE in T lympho-
cytes and in skeletal muscle is the kinetics of CRAC-
channel activation. In T lymphocytes, the kinetics of
SOCE activation by store depletion is relatively slow with
a delay of tens of seconds between store depletion and
SOCE. In contrast, in skeletal muscle the local activation
of SOCE by store depletion is almost instant (less than 1
second delay) and graded in nature, as shown in recent
studies by Launikonis [91,92]. Hence, it was proposed that
pre-localization of STIM1 and Orai1 at TC/T-tubule junc-
tions under basal conditions when SR stores are fully
loaded with Ca
2+ underpins the fast kinetics (Figure 2).
The pre-localization of STIM1 in the SR at triad junctions
was observed in differentiated myotubes of the C2C12 cell
line as well as in native skeletal muscle from the hind
limbs of adult mice [63,85]. The exact molecular architec-
ture of the inactive STIM1/Orai1 complexes in resting
skeletal-muscle cells remains to be elucidated. Two mod-
els that allow for rapid SOCE activation upon SR Ca
2+-
store depletion were proposed by Dirksen [76]. In model
1, STIM1 monomers are localized in the vicinity of inac-
tive Orai1 channels at the triad junctions. A decrease in
the SR [Ca
2+] will cause rapid dissociation of Ca
2+ from
STIM1, resulting in conformational changes in STIM1, its
oligomerization and activation of the pre-localized Orai1
channels. In model 2, STIM1 exists in pre-formed com-
plexes with the C-terminal region of inactive Orai1 chan-
nels, which remain silent until a decrease in SR [Ca
2+]
triggers conformational changes in STIM1 and direct acti-
vation of Orai1-mediated Ca
2+ influx, for example through
Figure 2 Regulators of SOCE in skeletal muscle. At the triad junction, the voltage-sensitive DHPR (Cav1.1) and RyR physically interact.
Depolarization of the plasma membrane causes activation of DHPR and subsequent opening of intracellular Ca
2+-release channels, like the most
abundant RyR isoform in skeletal muscle, RyR1. In addition, STIM1 monomers and/or oligomers accumulate at the terminal cisternae of the SR,
thereby being in close proximity or in complex with Orai1. This pre-localization of STIM1 with Orai1 likely accounts for the fast-activation kinetics
of SOCE. Furthermore, it may also account for a basal Ca
2+ influx through Orai1 channels in resting conditions. As a consequence, STIM1/Orai1
complexes are an integral part of the Ca
2+-homeostasis mechanisms responsible for maintaining proper SERCA1-mediated filling of the SR Ca
2+
stores and sustaining resting [Ca
2+] in the cytosol. The highly specialized and structural organization of the triad in close proximity of the SR to
plasma-membrane SOCE, which involves junctophilin, seems to be essential for proper STIM1/Orai1-mediated Ca
2+ homeostasis. A similar
mechanism involving TRPC channels and STIM1 oligomers have also been implicated in Ca
2+-influx mechanisms in the skeletal muscle, although
STIM1-dependent regulation of TRPCs is a matter of debate. Abbreviations: DHPR, dihydropyridine receptor; RyR, ryanodine receptor; SOCE, store-
operated Ca
2+ entry; STIM, stromal interaction molecule; SR, sacroplasmic reticulum; TRPC, canonical transient receptor potential.
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The latter would allow for an ultra-fast, efficient and
tightly controlled activation of Orai1.
In any case, the spatial organization of triad-junction
structure, which allows close contacts between the TC of
t h eS Ra n dt h et r a n s v e r s et u b u l a ri n v a g i n a t i o n so ft h e
plasma membrane, seems to be the key for efficient
SOCE in skeletal muscle [93]. Indeed, disrupting the
triad structure in skeletal-muscle fibers by acute suppres-
sion of junctophilin 1/2, a protein responsible for form-
ing the close contacts between the intracellular stores
and the plasma membrane (Figure 2), leads to reduced
SOCE, a decrease in the SR Ca
2+ content and altered caf-
feine-triggered RyR-mediated Ca
2+ response. Hence,
structural properties of the triad junctions seem to be
responsible for the efficient coupling of retrograde signal-
ing from the SR to T-tubules, thereby controlling SOCE,
and overall Ca
2+ homeostasis and muscle physiology.
These features may be important in explaining the effect
of pathophysiological mutations in junctophilins or
altered junctophilin-expression profiles that are asso-
ciated with cardiac failure or muscle aging [94,95]. Very
recently, reduced SOCE in junctophilin-1 knock out
myotubes was associated with a decline in STIM1/Orai1-
expression levels and a reduced resting cytosolic [Ca
2+]
and SR Ca
2+ content [96]. Using a Ca
2+-entry blocker,
BTP2, Eltit and co-workers showed that Ca
2+ influx was
essential for maintaining proper resting [Ca
2+], since
treating wild-type myotubes with BTP2 caused a decrease
in SOCE and in resting [Ca
2+], resembling the situation
in junctophilin-1 knock out myotubes [96]. Since differ-
ent Ca
2+-entry mechanisms may account for this phar-
macological effect, the authors elegantly used the
dominant negative Orai1 form, Orai1 E190Q. Strikingly,
expression of Orai1 E190Q was sufficient to inhibit
SOCE in wild-type myotubes and to decrease the resting
[Ca
2+], while it had no effect in junctophilin-1 knock out
myotubes. As a consequence, wild-type myotubes expres-
sing Orai1 E190Q displayed a reduced SR Ca
2+ content.
Hence, this study is one of the first to show that Orai1-
mediated SOCE is critical to control resting cytosolic
[Ca
2+]a n dS RC a
2+ content. This further supports the
concept that SOCE is an essential feature for proper
muscle function, not only during conditions of intensive
stimulation, but also during resting conditions.
It is also conceivable that other plasma-membrane
channels may contribute to the pre-localization of
STIM1 to the TC/t-tubule junctions. The identification
of the a1c subunit of the voltage-gated Cav1.2 channel
as a novel target of STIM1 [58,59] may point towards a
more general role for voltage-gated Ca
2+ channels to
target STIM1 in spatially or functionally restricted
domains. Although the DHPR L-type Ca
2+-channel
(a1s) differs in properties with a1c, it is possible that
STIM1 interacts with both.
STIM1 in physiological signaling
Recently, it became clear that SOCE plays a prominent
role in muscle development and muscle function and
that STIM1 hereby has a central role [63,93,96,97]
(Figure 3). For example, mice deficient in STIM1 signal-
ing displayed defects in muscle differentiation and con-
tractile activity [63]. Homozygous STIM1-deficient
neonatal mice died from a perinatal myopathy, whereas
STIM1-haploinsufficient mice displayed increased sus-
ceptibility to fatigue. These data indicate that STIM1
controls both chronic Ca
2+-controlled signaling pro-
cesses, like muscle differentiation and remodeling
through the activation of a genetic program, as well as
acute Ca
2+-signaling processes such as muscle contrac-
tion, by supporting the adequate function of the con-
tractile system under conditions of prolonged motor-
nerve activity.
Underlying these phenomena is STIM1-dependent
activation of NFAT in skeletal muscle, which drives myo-
genesis and muscle differentiation [63]. It has been
known for a long time that a dramatic remodeling of
Ca
2+-transport mechanisms underlies and accompanies
skeletal-muscle differentiation. Differentiation of BC3H1
cells to a muscular phenotype was characterized by a
decrease in IP3-induced Ca
2+ release and an increase in
Ca
2+-pump activity as well as in caffeine-induced Ca
2+
release [98]. Also during C2C12 differentiation from
myoblasts to multinucleated myotubes, IP3R-expression
levels declined, while the expression levels of RyR1 Ca
2+-
release channels and SERCA2a/SERCA1 Ca
2+ pumps
dramatically augmented [99]. A recent study of Stiber
et al. [63] now adds STIM1 as another molecular factor,
whose expression level increases and whose localization
changes from perinuclear to cell peripheral upon differ-
entiation of C2C12 myoblasts into myotubes. These
molecular findings correlate with the increased rate of
Ca
2+ influx in these cells upon thapsigargin-induced SR
Ca
2+-store depletion.
Independently, we have examined STIM1- and STIM2-
protein levels together with the expression of other Ca
2
+-handling proteins, like Orai1, SERCA1, SERCA2a, RyRs
and IP3Rs in differentiating C2C12 cells (Figures 4A and
4B). We could confirm the up-regulation of STIM1 and
Orai1 in C2C12 cells undergoing differentiation. However
we observed a transient up-regulation of STIM1, while
Orai1 is permanently augmented. Strikingly, the maximal
STIM1 levels correlate with the up-regulation of Orai1,
but precede the up-regulation of SERCA1, SERCA2a and
RyR. In contrast, STIM2 levels did not significantly change
during C2C12 differentiation, suggesting a selective role
for STIM1 in skeletal-muscle differentiation. STIM1
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tal-muscle differentiation. Nevertheless, this transient
STIM1 up-regulation seems to correlate with the observa-
tions of Stiber et al. in muscle formation during develop-
ment in vivo [63].
It is possible that the transient STIM1 up-regulation,
which seems to occur as an intermediate step between
myogenin and SERCA/RyR up-regulation, is needed for
increasing Ca
2+ influx and is required for driving the
remodeling of the Ca
2+-handling proteins through
Ca
2+-dependent NFAT signaling (Figure 4C). Indeed,
Stiber et al. have shown that STIM1 silencing with
short hairpin RNA decreased basal NFAT trans-activa-
tion in differentiated myotubes, while constitutively
active STIM1 expression increased basal NFAT trans-
activation [63]. Furthermore, NFAT is known to con-
trol muscle formation through morphogenetic events
that depend on Ca
2+-dependent signaling through the
activation of calcineurin/NFAT [100,101].
The critical role of STIM1 in skeletal-muscle develop-
ment was further demonstrated by Stiber et al. using a
gene trap approach resulting in the expression of STIM1/
LacZ-fusion proteins (STIM1
gt), which contained the N-
terminal EF-SAM domain and the transmembrane
domain of STIM1 [63]. Most homozygous STIM1
gt/gt
mice died at a neonatal stage. However, surviving mice
displayed decreased body weight, impaired muscle forma-
tion and increased fatigue. Studies revealed that the SOC
currents in response to thapsigargin were completely
abolished in primary myotubes deficient of STIM1.
STIM1 deficiency caused a severe impairment of the
skeletal-muscle structure and function. STIM1 loss also
resulted in increased central nucleation, a reduced muscle
cross-sectional area, swollen mitochondria and a decline
in the muscle-specific proteins in the SR, like SERCA1
and myosin heavy chain. In addition, the levels of MyoD,
one of the master regulatory genes that controls muscle
differentiation, were lower in the muscle of STIM1-
deficient mice. At the functional level, loss of STIM1 led
to a decrease in the maximal tetanic force and in the fati-
gue resistance. The latter could be attributed to an
impaired SR Ca
2+-store filling in the myotubes. After on-
going depolarization pulses, the content of the SR Ca
2+
stores was severely reduced in STIM1
gt/gt myotubes in
contrast to their wild-type counterparts. This indicates
that STIM1-controlled SOCE is required to refill the inter-
nal SR Ca
2+ stores during repeated stimulations. The latter
has been confirmed by another study showing the rapid
Figure 3 Schematic overview of the physiological role of SOCE in skeletal muscle and pathophysiological consequences of Ca
2+-influx
dysregulation based on mouse-model studies. STIM1-controlled Ca
2+ influx, either through Orai1 or TRPC channels, ought to be tightly
regulated for proper muscle development and function. STIM1-gated Orai1-mediated Ca
2+ influx seems to be a requisite for proper Ca
2+
homeostasis in the skeletal muscle, maintaining resting cytosolic [Ca
2+] sufficiently high and adequately filling the SR Ca
2+ stores. This constitutes
an essential mechanism that compensates for Ca
2+ losses to the extracellular space. Importantly, these phenomena may not only act during
periods of intense stimulation, but may also be required during basal conditions and regular muscle function. On the one hand, suppressing
Ca
2+ influx, for example in STIM1-deficient muscle fibers, leads to improper muscle development and function. This is likely due to hampered
activation of NFAT-dependent signaling and defective expression of Ca
2+-handling proteins, such as SERCAs and RyRs, as well as other proteins
involved in muscle contraction. On the other hand, events such as mutations in dystrophin or overexpression of TRPC channels, lead to muscle
dystrophy and degeneration, likely due to mitochondrial Ca
2+ overload and Ca
2+-dependent activation of the apoptotic program. Abbreviations:
NFAT, nuclear factor of activated T cells; RyR, ryanodine receptor; SERCA, sarcoplasmic/endoplasmic-reticulum Ca
2+-ATPase; SR, sacroplasmic
reticulum; STIM, stromal interaction molecule; TRPC, canonical transient receptor potential.
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2+-handling proteins including STIM1, STIM2 and Orai1 during myogenic differentiation of C2C12 cells.A :
Representative panel of Western blots for each protein of interest in lysates from C2C12 cells in an undifferentiated state and different stages of
differentiation. B: Graph represents the average expression of three independent biological samples (mean ± S.E.M.) of C2C12 cells undergoing
differentiation. All values were normalized to GAPDH, which was used as a loading control. C: A model for key proteins involved in the proper
remodeling of myoblasts into myotubes, based on previous reports [99] and own data. The expression pattern of myogenin, taken from the
study of MacLennan and co-workers [99], was up-regulated starting from day 1 of myoblast differentiation, which would mark the first wave of
differentiation [99]. Orai1, SERCA2a and RyR1 started to emerge at day 3, while cells exhibit a transient cardiac phenotype. Interestingly, we also
observed an even shorter transient of STIM1 up-regulation, which seemed to decline at the same time as SERCA1 levels increased. Remarkably,
while STIM1 was transiently up-regulated, STIM2 did not significantly alter and Orai1 continued to increase during differentiation. Materials and
methods: Cells were collected 0, 1, 3 or 5 days after replacing myoblast culture medium with myotube differentiation medium [99,113]. Cell
lysates were analyzed for protein expression by Western blot and expression was each time normalized to GAPDH expression. Signals were
detected with ECF and analyzed with ImageJ. Antibodies were from ProSci Inc., Poway, CA, USA (Orai1), Sigma, St Louis, MO, USA (STIM2 and
GAPDH), Abnova, Taipei City, Taiwan (STIM1) and Thermo Scientific, Rockford, IL, USA (SERCA1 and RyR). The SERCA2a and IP3R1 antibodies are
described elsewhere [114,115]. Abbreviations: ECF, enhanced chemifluorescence; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP3R,
inositol 1,4,5-trisphosphate receptor; RyR, ryanodine receptor; SERCA, sarcoplasmic/endoplasmic-reticulum Ca
2+-ATPase; STIM, stromal interaction
molecule.
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2+ in the T-tubule system upon muscle-cell
depolarizations [91]. A critical function of STIM1 in SR
Ca
2+-store filling in human skeletal muscle needs to be
confirmed. However, the fact that SCID patients carrying
loss-of-protein expression mutations in the STIM1 gene,
manifest atrophy of the type-II skeletal-muscle fibers
resulting in severe chronic pulmonary disease [41], sup-
ports the concept that STIM1-mediated SOCE plays a
critical role in sustaining proper SR Ca
2+-store filling and
skeletal-muscle function in humans.
STIM1 in pathophysiological signaling
While STIM1 and SOCE seem to be essential for skele-
tal-muscle development, excessive store-operated Ca
2+
influx may underpin pathological conditions, like Duch-
enne muscular dystrophy [74]. A crucial feature of this
disease is defective expression of dystrophin. Myotubes
lacking functional dystrophin display altered Ca
2+
dynamics, characterized by exaggerated SOCE [74,102].
The latter may be responsible for the observed sustained
cytosolic Ca
2+ transients and increased Ca
2+ uptake by
the mitochondria. Importantly, re-introduction of mini-
dystrophin reduces Ca
2+ entry to its normal level, which
leads to shorter Ca
2+ transients and decreased mito-
chondrial Ca
2+ uptake [74]. Although these studies did
not clarify the involvement or role of STIM1, they point
towards a critical regulation of proper SOCE for the
physiological function of skeletal cells. Indeed, SOCE
apparently needs to be tightly regulated, since sup-
pressed as well as exaggerated SOCE underpin skeletal-
muscle dysfunction [63,74]. An elegant study recently
published by the Molkentin lab indicated that increased
Ca
2+ entry by itself is sufficient to induce muscular dys-
trophy in vivo, since transgenic mice overexpressing
TRPC3 channels are characterized by features similar to
the dystrophic disease models [75].
Different molecular mechanisms of increased Ca
2+ entry
underpinning this disease model have been proposed,
including store-operated and stretch-operated ion chan-
nels [103]. On the one hand, TRPC channels seem impor-
tant candidates [75]. Indeed, mdx dystrophic skeletal-
muscle fibers displayed increased TRPC-mediated Ca
2+
influx [73,75]. Interestingly, TRPC1 has been shown to
associate with the dystrophin-protein complex [104,105].
Moreover, dystrophic skeletal-muscle disease models asso-
ciated with mutations in the dystrophin or mutations in
the delta-Sarcoglycan (Scgd) genes were rescued by trans-
gene-mediated inhibition of TRPC channels, thereby redu-
cing Ca
2+ influx and preventing the development of
muscular-dystrophy features [75]. On the other hand, Lau-
nikonis and co-workers demonstrated that while SOCE
functions normally in mdx muscle fibers, the thresholds
for activation and deactivation of SOCE have been shifted
to higher SR [Ca
2+] [106]. This may contribute to higher
Ca
2+ influx during long periods of stimulation. The
molecular basis for these shifts in threshold may be asso-
ciated with the dramatic increase in STIM1/Orai-protein
levels found in the mdx muscle fibers [106]. Interestingly,
these data may correlate with our observations suggesting
a transient up-regulation of STIM1 during muscle differ-
entiation, while a permanent up-regulation of STIM1 may
contribute to deleterious muscle events.
Independently of the mechanism, preventing Ca
2+
influx may be beneficial and holds potential for future
therapeutic strategies to tackle muscular dystrophy
either by targeting STIM1/Orai1 or TRPC channels,
since both channel complexes have been shown to be
implicated and/or up-regulated in Duchenne muscular
dystrophy models [75,106]. All studies seem to agree on
the fact that excessive SOCE is an early event in this
pathology and that inhibiting SOCE seems to be benefi-
cial. This paradigm is supported by different studies:
i) TRPC suppression rescues muscular dystrophic fea-
tures in mouse models [75]; ii) blockers of stretch-acti-
vated channels prevent muscle degeneration in mdx
mice [107]; iii) inhibitors of phospholipase A2, which is
overexpressed in skeletal muscle of a mouse model for
Duchenne muscular dystrophy, attenuate the exagger-
ated SOCE and the subsequent muscle damage [102].
Furthermore, while reducing Ca
2+ influx may be criti-
cal for targeting this pathology, inhibiting Ca
2+ release
from the ER has also been shown to be beneficial [108].
For instance, overexpression of anti-apoptotic Bcl-2 pre-
vented IP3R-mediated Ca
2+ release [109,110] and subse-
quent mitochondrial Ca
2+ overload, thereby protecting
dystrophic muscle cells against Ca
2+-dependent apopto-
sis [108]. Hence, a concerted strategy to alleviate muscu-
lar dystrophy likely requires the dampening of both Ca
2+
influx as well as ER Ca
2+ release.
Finally, it is important to note that most of the evi-
dence that points towards excessive Ca
2+ influx as an
early event in the development of muscular dystrophy
has been obtained from mouse models. We need to
keep in mind that the need and physiological role of
SOCE might be different for mouse and human skeletal
muscle. For instance, a micro-array analysis of human
skeletal-muscle biopsies from control patients and
Duchenne muscular dystrophy patients (obtained from
the Gene Expression Omnibus; http://www.ncbi.nlm.nih.
gov/geo/) indicated that the STIM1-mRNA levels were
not increased, but rather tended to decrease in the mus-
cle of the dystrophic patients, while Orai1-mRNA levels
were not significantly changed (Figure 5). This seems in
contrast with the up-regulation of STIM1 and Orai1
and the increased SOCE reported in mouse models for
Duchenne muscular dystrophy. These contrasting find-
ings may indicate that mechanisms underpinning SOCE
are differently affected in the human muscular patholo-
gies versus the mouse models for these pathologies. In
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STIM2 for SOCE in human muscles and their contribu-
tion to myopathies may differ among human and mice.
In this respect, Duchenne muscular dystrophy patients
did show an up-regulation of STIM2-mRNA levels,
which is activated at more modest decreases in [Ca
2+]ER
than STIM1. Therefore, STIM2 up-regulation may be
another critical factor that needs to be taken into
account in the development of muscular dystrophy in
human patients. In any case, it is clear that the role of
both STIM proteins for the development of myopathies
in human patients must be further explored.
Moreover, other mechanisms may account for the
excessive Ca
2+ influx that leads to muscle degeneration in
human patients. Therefore, it is important to note that
TRPC1-mRNA levels are also significantly up-regulated in
the patients suffering from muscular dystrophy. Impor-
tantly, excessive TRPC1 activity has been implicated in
Figure 5 Gene expression involved in Ca
2+ and/or contractility. Plots represent gene expression in quadriceps skeletal-muscle samples of
controls (CTL, n = 10-12) and patients with Duchenne muscular dystrophy (DMD, n = 10 - 12) in arbitrary units (A.U.). Data were obtained from
GEO reference series GSE1007 (STIM1, STIM2, ORAI1, ITPR1 and CASQ1) and GSE1004 (TRPC1, ATP2A1, RYR1 and MYH2) [116-118] comparing the
mRNA-expression levels in normal and dystrophic patients (http://www.ncbi.nlm.nih.gov/geo/). Graphs represent box plots, indicating the mean
(square symbol), the median (line), the 25
th and 75
th percentiles (bottom and top of the box), and the 5
th and 95
th percentiles (whisker range).
Strikingly, STIM1-, SERCA1-, RyR1-mRNA levels tended to decline, while STIM2-, TRPC1- and IP3R1-mRNA levels tended to increase. Orai1-,
calsequestrin-1- and myosin heavy chain-2-mRNA levels did not significantly alter. This seems opposite to what has been observed in mouse
models for Duchenne muscular dystrophy, which displayed excessive Ca
2+ influx and up-regulation of STIM1/Orai1 [106]. In human patients
suffering from Duchenne muscular dystrophy, TRPC1 elevations may account for the increase in Ca
2+ influx, leading to Ca
2+-dependent
apoptosis and muscle degeneration. This indicates that caution should be taken from extrapolating results from mouse models for
pathophysiological conditions to human pathophysiological conditions. Abbreviations indicate the gene names for stromal interaction molecule
1( STIM1), stromal interaction molecule 2 (STIM2), Orai1 (ORAI1), canonical transient receptor potential 1 (TRPC1), sarcoplasmic/endoplasmic-
reticulum Ca
2+-ATPase 1 (ATP2A1), ryanodine receptor 1 (RYR1), inositol 1,4,5-trisphosphate receptor 1 (ITPR1), calsequestrin 1 (CASQ1), and myosin
heavy chain IIa (MYH2).
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2+ influx and the activation of Ca
2+-depen-
dent proteolysis, leading to the degradation of cytoskeletal
proteins and the development of myopathies in Homer
1-deficient mice [111]. Decreased levels of Homer 1 in
mdx mouse models may contribute to the reported
TRPC1 hyperactivity in response to store depletion [73].
However, the contribution of STIM1 in this process
remains unknown.
Finally, these micro-array analyses also revealed that
SERCA1- and RyR1-mRNA levels declined, IP3R1-
mRNA levels increased and Orai1-, calsequestrin-1- and
myosin heavy chain-2-mRNA levels did not significantly
alter. Changes in IP3R-expression level have previously
been shown to occur in patient samples of Duchenne
muscular dystrophy [112]. This indicates a remodeling
of the Ca
2+-handling mechanisms that tends to shift to
the undifferentiated state, while proteins involved in the
contractile mechanism are not profoundly affected. In
any case, it would be interesting to elucidate whether
the changes in Ca
2+-transport mechanisms correlate
with the severity of the disease.
Conclusions
While the role of SOCE is well established in T cells
and other non-excitable cells, it is becoming clear that
SOCE may play a very important role in skeletal-muscle
physiology, ranging from roles in development, differen-
tiation, contractile function and resistance against fati-
gue. STIM1 plays a central role in these processes by
controlling SOCE channels, like Orai1 and/or TRPCs in
a rapid and highly regulated fashion. While physiological
SOCE is required for proper muscle development and
function, excessive SOCE seems to be detrimental for
skeletal muscle. Indeed, promoting Ca
2+ influx by over-
expressing TRPCs is sufficient to degenerate healthy
muscle, while genetic mouse models for muscular dys-
trophy have been characterized by excessive SOCE.
From these studies, it is clear that STIM1 function and
thus SOCE ought to be tightly regulated for proper
muscle physiology.
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